Healthcare provider profile · identity verified

Makayla Batis

Physician Assistant · BRATTLEBORO, VT · NPI 1336762699

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	199	54
Atorvastatin Calcium	Atorvastatin Calcium	173	44
Lisinopril	Lisinopril	154	41
Omeprazole	Omeprazole	143	38
Pantoprazole Sodium	Pantoprazole Sodium	99	23
Oxycodone Hcl	Oxycodone Hcl	98	19
Albuterol Sulfate Hfa	Albuterol Sulfate	86	24
Amlodipine Besylate	Amlodipine Besylate	84	26
Losartan Potassium	Losartan Potassium	80	20
Gabapentin	Gabapentin	76	20
Metoprolol Succinate	Metoprolol Succinate	76	23
Sertraline Hcl	Sertraline Hcl	71	19
Rosuvastatin Calcium	Rosuvastatin Calcium	70	27
Escitalopram Oxalate	Escitalopram Oxalate	68	17
Tramadol Hcl	Tramadol Hcl	65	19
Eliquis	Apixaban	61	suppressed
Trazodone Hcl	Trazodone Hcl	60	17
Furosemide	Furosemide	57	13
Simvastatin	Simvastatin	52	18
Pravastatin Sodium	Pravastatin Sodium	51	13
Ozempic	Semaglutide	50	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	48	15
Montelukast Sodium	Montelukast Sodium	47	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	46	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	43	11
Aripiprazole	Aripiprazole	41	11
Fluoxetine Hcl	Fluoxetine Hcl	41	suppressed
Lorazepam	Lorazepam	41	21
Metoprolol Tartrate	Metoprolol Tartrate	36	15
Pregabalin	Pregabalin	36	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	12
Metformin Hcl	Metformin Hcl	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Bupropion Xl	Bupropion Hcl	31	13
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Meloxicam	Meloxicam	29	11
Buspirone Hcl	Buspirone Hcl	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Topiramate	Topiramate	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Clonazepam	Clonazepam	21	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	11
Alprazolam	Alprazolam	19	suppressed
Carvedilol	Carvedilol	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Estradiol	Estradiol	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Jardiance	Empagliflozin	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Budesonide Ec	Budesonide	13	suppressed
Cephalexin	Cephalexin	13	suppressed
Diazepam	Diazepam	13	suppressed
Famotidine	Famotidine	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Atenolol	Atenolol	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error